Literature DB >> 22734882

Short communication: HIV type 1 accumulates in influenza-specific T cells in subjects receiving seasonal vaccination in the context of effective antiretroviral therapy.

R Brad Jones1, Colin Kovacs, Tae-Wook Chun, Mario A Ostrowski.   

Abstract

Whether or not HIV-1 continues to infect cells in individuals treated with effective antiretroviral therapy (ART) remains controversial. Here, we determined whether the redistribution of the HIV-1 proviral burden with respect to antigen specificity of CD4(+) cells would provide evidence for ongoing infection cycles in vivo. HIV-1 preferentially infects antigen-stimulated CD4(+) T cells. In the setting of prolonged effective ART, we postulated that if infection cycles were occurring, influenza-specific CD4(+) T cells, activated by influenza vaccination, would preferentially accumulate proviral burden. Peripheral blood mononuclear cells (PBMCs) were collected from HIV-1-infected subjects who had been treated with effective ART for >5 years, before and after influenza vaccination. CD4(+) T cells were sorted by antigen specificity and HIV-1 proviral burdens were determined. Levels of HIV-1 production upon in vitro antigenic stimulation were also measured. At baseline, influenza-specific CD4(+) T cells carried higher HIV-1 proviral loads than HIV-1-p55-specific CD4(+) T cells. Upon influenza vaccination we observed trends toward elevated levels of HIV-1 proviral DNA in influenza and HIV-1-p55-specific, but not tetanus toxoid or cytomegalovirus (CMV)-specific CD4(+) T cells. Higher levels of HIV-1 virions were produced upon influenza stimulation in postvaccination as compared to baseline samples. While the trends toward increased proviral burdens in influenza-specific cells failed to reach statistical significance, our observation of disproportionately high levels of provirus in influenza-specific cells at baseline indicates that this may represent a real increase that is cumulative over multiple annual vaccinations. This has implications for the eradication of HIV-1 by adding to the evidence that the resting CD4(+) T cell viral reservoir is continually replenished in ART-treated subjects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22734882      PMCID: PMC3505056          DOI: 10.1089/AID.2012.0115

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  37 in total

1.  Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication.

Authors:  Bharat Ramratnam; Ruy Ribeiro; Tian He; Chris Chung; Viviana Simon; Jeroen Vanderhoeven; Arlene Hurley; Linqi Zhang; Alan S Perelson; David D Ho; Martin Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2004-01-01       Impact factor: 3.731

2.  Transient elevation of serum HIV antigen levels associated with intercurrent infection.

Authors:  E J Claydon; J Bennett; D Gor; S M Forster
Journal:  AIDS       Date:  1991-01       Impact factor: 4.177

3.  Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS.

Authors:  D Zagury; J Bernard; R Leonard; R Cheynier; M Feldman; P S Sarin; R C Gallo
Journal:  Science       Date:  1986-02-21       Impact factor: 47.728

4.  HIV preferentially infects HIV-specific CD4+ T cells.

Authors:  Daniel C Douek; Jason M Brenchley; Michael R Betts; David R Ambrozak; Brenna J Hill; Yukari Okamoto; Joseph P Casazza; Janaki Kuruppu; Kevin Kunstman; Steven Wolinsky; Zvi Grossman; Mark Dybul; Annette Oxenius; David A Price; Mark Connors; Richard A Koup
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

5.  A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

Authors:  Hiroyu Hatano; Timothy L Hayes; Viktor Dahl; Elizabeth Sinclair; Tzong-Hae Lee; Rebecca Hoh; Harry Lampiris; Peter W Hunt; Sarah Palmer; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Barbara L Shacklett; Steven G Deeks
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

6.  Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Authors:  Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation.

Authors:  P N Fultz; J C Gluckman; E Muchmore; M Girard
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

8.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

9.  HIV-1 replication is controlled at the level of T cell activation and proviral integration.

Authors:  M Stevenson; T L Stanwick; M P Dempsey; C A Lamonica
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

10.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

Authors:  M E Sharkey; I Teo; T Greenough; N Sharova; K Luzuriaga; J L Sullivan; R P Bucy; L G Kostrikis; A Haase; C Veryard; R E Davaro; S H Cheeseman; J S Daly; C Bova; R T Ellison; B Mady; K K Lai; G Moyle; M Nelson; B Gazzard; S Shaunak; M Stevenson
Journal:  Nat Med       Date:  2000-01       Impact factor: 87.241

View more
  4 in total

1.  Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivo.

Authors:  Francesco R Simonetti; Hao Zhang; Garshasb P Soroosh; Jiayi Duan; Kyle Rhodehouse; Alison L Hill; Subul A Beg; Kevin McCormick; Hayley E Raymond; Christopher L Nobles; John K Everett; Kyungyoon J Kwon; Jennifer A White; Jun Lai; Joseph B Margolick; Rebecca Hoh; Steven G Deeks; Frederic D Bushman; Janet D Siliciano; Robert F Siliciano
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

2.  Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir.

Authors:  Pilar Mendoza; Julia R Jackson; Thiago Y Oliveira; Christian Gaebler; Victor Ramos; Marina Caskey; Mila Jankovic; Michel C Nussenzweig; Lillian B Cohn
Journal:  J Exp Med       Date:  2020-07-06       Impact factor: 14.307

3.  Persistence of Unintegrated HIV DNA Associates With Ongoing NK Cell Activation and CD34+DNAM-1brightCXCR4+ Precursor Turnover in Vertically Infected Patients Despite Successful Antiretroviral Treatment.

Authors:  Lucia Taramasso; Federica Bozzano; Anna Casabianca; Chiara Orlandi; Francesca Bovis; Sara Mora; Mauro Giacomini; Lorenzo Moretta; Mauro Magnani; Antonio Di Biagio; Andrea De Maria
Journal:  Front Immunol       Date:  2022-04-26       Impact factor: 8.786

4.  SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells.

Authors:  Eva M Stevenson; Sandra Terry; Dennis Copertino; Louise Leyre; Ali Danesh; Jared Weiler; Adam R Ward; Pragya Khadka; Evan McNeil; Kevin Bernard; Itzayana G Miller; Grant B Ellsworth; Carrie D Johnston; Eli J Finkelsztein; Paul Zumbo; Doron Betel; Friederike Dündar; Maggie C Duncan; Hope R Lapointe; Sarah Speckmaier; Nadia Moran-Garcia; Michelle Premazzi Papa; Samuel Nicholes; Carissa J Stover; Rebecca M Lynch; Marina Caskey; Christian Gaebler; Tae-Wook Chun; Alberto Bosque; Timothy J Wilkin; Guinevere Q Lee; Zabrina L Brumme; R Brad Jones
Journal:  Nat Commun       Date:  2022-08-19       Impact factor: 17.694

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.